Biotech startups in California, United States
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Multiply Labs | San Francisco | Series B | $75.0M | 2026-10-06 |
| Craif | Irvine | Series D | $24.4M | 2026-08-18 |
| Chai Discovery | San Francisco | Series C | $400.0M | 2026-07-14 |
| Prolific Machines | Emeryville | Series B | $50.0M | 2026-10-14 |
| Profluent Bio | Emeryville | Series B | $106.0M | 2025-11-19 |
| BigHat Biosciences | San Mateo | Series C | $75.0M | 2026-09-24 |
| TwoStep Therapeutics | Palo Alto | Series A | $62.5M | 2026-09-09 |
| BillionToOne | Menlo Park | Series D | $130.0M | 2024-06-21 |
8 rows of the CSV in 5 of its 18 columns.
- The 1,577 biotech startups in California, United States have raised $77.4B in total.
- 228 of them closed their most recent round in the last 12 months, $8.1B combined.
- The largest of those rounds is Chai Discovery's $400.0M Series C, dated July 2026.
- The most recent is Zafrens' $6.0M Series A on 3 November 2026.
- Y Combinator is an investor in 49 of them, more than any other fund.
- Health care is the most common other sector, with 1,257 companies (80%).
- 33% were founded in 2020 or later; the median founding year is 2017.
- The most common team size is 1 to 10 employees (42% of companies with a recorded size).
- 7 are unicorns, valued at $1 billion or more.
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
30 of 1,577| Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Zafrens | Zafrens provides a throughput platform that links molecular profiles to cell phenotypes for drug discovery. | Biotech | San Diego | Series A | $6.0M | 2026-11-03 | $35.0M | Liquid 2 Ventures, Global Brain Corporation, BlueYard Capital +2 | 11 to 50 | 2022 |
| Probably Genetic | Probably Genetic develops treatments aimed at improving the lives of patients with severe, complex diseases. | Artificial intelligence | San Francisco | Series A | $12.0M | 2026-10-15 | $22.9M | Y Combinator, Khosla Ventures, TenOneTen Ventures +2 | 11 to 50 | 2018 |
| Prolific Machines | Prolific Machines develops light-controlled gene expression systems for producing therapeutics. | Artificial intelligence | Emeryville | Series B | $50.0M | 2026-10-14 | $147.0M | SOSV, Mayfield Fund, SOSV SF & NY (Fka IndieBio) +2 | 51 to 100 | 2020 |
| Welltory | Welltory produces AI-powered wellness apps for digital health tracking. | Artificial intelligence | Redwood City | Seed | $2.0M | 2026-10-08 | $16.3M | Goodwater Capital, JOINT JOURNEY, CABRA VC | 51 to 100 | 2016 |
| Multiply Labs | Multiply Labs builds robotic systems that automate biologics manufacturing. | Artificial intelligence | San Francisco | Series B | $75.0M | 2026-10-06 | $97.7M | Y Combinator, Founders Fund, Garage Capital +2 | 11 to 50 | 2016 |
| BigHat Biosciences | BigHat Biosciences develops antibody and protein therapeutics using machine learning and automated experimentation. | Artificial intelligence | San Mateo | Series C | $75.0M | 2026-09-24 | $174.3M | Andreessen Horowitz, Gaingels, 8VC +2 | 51 to 100 | 2019 |
| ImpriMed | ImpriMed provides AI-driven precision medicine services to oncologists and pharmaceutical companies. | Artificial intelligence | Palo Alto | Series A | $10.0M | 2026-09-18 | $44.7M | Plug and Play, Pear VC, Draper Associates +1 | 51 to 100 | 2017 |
| Circle Pharma | Circle Pharma develops bioavailable macrocyclic peptide therapeutics that target protein-protein interactions. | Biotech | South San Francisco | Series E | $92.5M | 2026-09-16 | $300.0M | Mission BioCapital, Pfizer, The Column Group +1 | 11 to 50 | 2012 |
| Mithrl | Mithrl is a software development company that builds custom NGS data workflows on demand. | Artificial intelligence | San Francisco | Series A | $20.0M | 2026-09-15 | $24.0M | Bonfire Ventures | 51 to 100 | 2023 |
| PGxAI | PGxAI provides a clinical decision support platform for pharmacogenomics, medication safety, and real-world evidence. | Artificial intelligence | Palo Alto | Seed | $3.0M | 2026-09-14 | $5.0M | ATEM Capital Fund LP | 11 to 50 | 2023 |
| TwoStep Therapeutics | TwoStep Therapeutics develops tumor-targeting therapeutics for solid tumors. | Biotech | Palo Alto | Series A | $62.5M | 2026-09-09 | $90.1M | NFX, 2048 Ventures, Alexandria Venture Investments +1 | 11 to 50 | 2023 |
| Moonwalk Biosciences | Moonwalk Biosciences develops precision epigenetic medications through its genomic medicine platform. | Artificial intelligence | South San Francisco | Series B | $70.0M | 2026-09-08 | $127.0M | Google Ventures, Khosla Ventures, ARCH Venture Partners +2 | 11 to 50 | 2022 |
| N-Power Medicine | N-Power Medicine is a biotechnology company that uses AI to offer clinical research and drug development services. | Artificial intelligence | Redwood City | Series B | $32.0M | 2026-09-01 | $104.0M | Merck Global Health Innovation Fund | 101 to 250 | 2021 |
| Craif | Craif develops a cancer diagnosis algorithm using microRNA data and machine learning. | Artificial intelligence | Irvine | Series D | $24.4M | 2026-08-18 | $68.7M | Global Brain Corporation, VentureOut, ANRI +1 | 51 to 100 | 2018 |
| Aureka Biotechnologies | Aureka Biotechnologies uses AI to discover protein therapeutics and antibody treatments. | Artificial intelligence | Laguna Hills | Series B | $100.0M | 2026-08-10 | $168.4M | K2VC, NRL Capital | 11 to 50 | 2023 |
| Integrated Biosciences | Integrated Bio develops multimodal biological datasets and AI for drug discovery against age-related diseases. | Artificial intelligence | Redwood City | Series A | $68.4M | 2026-08-05 | $85.6M | Root Ventures, Reinforced Ventures, Mission BioCapital +2 | 11 to 50 | 2022 |
| Rybodyn | Rybodyn develops therapeutics that train the immune system to detect and eradicate cancer. | Biotech | San Diego | Seed | $1.3M | 2026-07-23 | $15.3M | SOSV, SOSV SF & NY (Fka IndieBio) | 11 to 50 | 2022 |
| Transcripta Bio | Transcripta Bio develops drugs at an accelerated pace with reduced risk. | Biotech | Palo Alto | Series A | $24.0M | 2026-07-22 | $34.4M | BlueYard Capital, Jazz Venture Partners | 11 to 50 | 2020 |
| Chai Discovery | Chai Discovery develops artificial intelligence models and software for protein engineering and molecular design. | Artificial intelligence | San Francisco | Series C | $400.0M | 2026-07-14 | $631.0M | Thrive Capital, OpenAI | 11 to 50 | 2024 |
| Lycia Therapeutics | Lycia Therapeutics develops technology using lysosome-targeting chimeras to degrade disease-causing proteins. | Biotech | South San Francisco | Series D | $75.0M | 2026-06-25 | $301.6M | Franklin Templeton, Alexandria Venture Investments, Invus +1 | 11 to 50 | 2019 |
| Cellanome | Cellanome uses synthetic biology and informatics methods to analyze multi-omics data. | Biotech | Redwood City | Series C | $75.9M | 2026-06-18 | $289.6M | Premji Invest, Synetro Group | 51 to 100 | 2020 |
| Kopra Bio | Kopra Bio develops viral immunotherapy treatments to cure cancer. | Biotech | San Francisco | Seed | $9.1M | 2026-06-16 | $9.7M | Y Combinator, Pioneer Fund | 1 to 10 | 2024 |
| Element Biosciences Unicorn | Element Biosciences develops genomic sequencing and multiomics technologies for drug discovery and diagnostic applications. | Biotech | San Diego | Series E | $277.0M | 2026-06-09 | $678.0M | RA Capital Management, Fidelity, Wellington Management +2 | 251 to 500 | 2017 |
| ParcelBio | ParcelBio develops RNA medicine delivery systems and therapeutic development platforms. | Biotech | San Francisco | Seed | $13.0M | 2026-05-07 | $13.5M | Y Combinator, Alumni Ventures, Pioneer Fund +2 | 1 to 10 | 2024 |
| LTZ Therapeutics | LTZ Therapeutics develops novel immunotherapies for cancer and other diseases with unmet clinical needs. | Biotech | San Francisco | Series B | $38.0M | 2026-05-06 | $125.0M | Qiming Venture Partners, Shunwei Capital, K2VC +1 | 11 to 50 | 2022 |
| Fermeate | Fermeate provides photomolecular fermentation technology that makes biomanufacturing more sustainable and efficient. | Biotech | San Francisco | Seed | $2.5M | 2026-04-27 | $2.5M | SOSV, SOSV SF & NY (Fka IndieBio) | 1 to 10 | 2024 |
| Terremoto Biosciences | Terremoto Biosciences develops medicines using lysine-based covalent chemistry. | Biotech | San Francisco | Series C | $108.0M | 2026-04-15 | $358.0M | OrbiMed, Novo Holdings, Third Rock Ventures +2 | 51 to 100 | 2021 |
| TippingPoint Biosciences | TippingPoint Biosciences develops therapeutics that target genome packaging states in diseases such as cancer. | Biotech | San Francisco | Seed | $4.5M | 2026-03-31 | $4.5M | SOSV, SOSV SF & NY (Fka IndieBio) | 1 to 10 | 2022 |
| Numerion Labs | Numerion Labs develops artificial intelligence systems for drug discovery using deep learning algorithms. | Artificial intelligence | San Francisco | Series D | $19.8M | 2026-03-19 | $241.4M | Y Combinator, Khosla Ventures, Creative Destruction Lab +1 | 11 to 50 | 2012 |
| Condor Software | Condor Software is a financial intelligence platform that connects clinical, operational, and financial data in real time. | Biotech | San Diego | Series A | $24.0M | 2026-03-18 | $29.5M | Plug and Play, MassChallenge, Pareto Holdings +1 | 11 to 50 | 2020 |
Table 1. Biotech startups in California, United States: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 1,577.
Largest rounds
Last 12 months| # | Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Chai Discovery | Chai Discovery develops artificial intelligence models and software for protein engineering and molecular design. | Artificial intelligence | San Francisco | Series C | $400.0M | 2026-07-14 | $631.0M | Thrive Capital, OpenAI | 11 to 50 | 2024 |
| 2 | Element Biosciences Unicorn | Element Biosciences develops genomic sequencing and multiomics technologies for drug discovery and diagnostic applications. | Biotech | San Diego | Series E | $277.0M | 2026-06-09 | $678.0M | RA Capital Management, Fidelity, Wellington Management +2 | 251 to 500 | 2017 |
| 3 | Mirador Therapeutics | Mirador Therapeutics develops precision medicines for immune-mediated diseases. | Biotech | San Diego | Series B | $250.0M | 2026-01-12 | $730.0M | OrbiMed, Fidelity, ARCH Venture Partners +1 | 11 to 50 | 2024 |
| 4 | Angitia Biopharmaceuticals | Angitia Biopharmaceuticals develops biologic therapies for musculoskeletal diseases. | Biotech | Westlake Village | Series D | $130.0M | 2026-02-05 | $406.0M | Legend Capital, OrbiMed, Oriza Holdings +1 | 51 to 100 | 2018 |
| 5 | Aspen Neuroscience | Aspen Neuroscience is a biotechnology company that develops personalized cell therapies and autologous regenerative medicine. | Biotech | San Diego | Series C | $115.0M | 2025-11-20 | $387.0M | Google Ventures, OrbiMed, EDBI +2 | 101 to 250 | 2018 |
| 6 | Terremoto Biosciences | Terremoto Biosciences develops medicines using lysine-based covalent chemistry. | Biotech | San Francisco | Series C | $108.0M | 2026-04-15 | $358.0M | OrbiMed, Novo Holdings, Third Rock Ventures +2 | 51 to 100 | 2021 |
| 7 | Profluent Bio | Profluent Bio designs new proteins and gene-editing tools using AI for medicine, agriculture, and science. | Artificial intelligence | Emeryville | Series B | $106.0M | 2025-11-19 | $150.0M | Insight Partners, Spark Capital, AIX Ventures +1 | 11 to 50 | 2022 |
| 8 | Aureka Biotechnologies | Aureka Biotechnologies uses AI to discover protein therapeutics and antibody treatments. | Artificial intelligence | Laguna Hills | Series B | $100.0M | 2026-08-10 | $168.4M | K2VC, NRL Capital | 11 to 50 | 2023 |
| 9 | Loyal | Loyal develops veterinary medicines to extend the healthy lifespan of senior dogs. | Biotech | San Francisco | Series C | $100.0M | 2026-02-11 | $237.1M | Khosla Ventures, First Round Capital, Quiet Capital +1 | 101 to 250 | 2019 |
| 10 | Circle Pharma | Circle Pharma develops bioavailable macrocyclic peptide therapeutics that target protein-protein interactions. | Biotech | South San Francisco | Series E | $92.5M | 2026-09-16 | $300.0M | Mission BioCapital, Pfizer, The Column Group +1 | 11 to 50 | 2012 |
Table 2. Biotech startups in California, United States: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Y Combinator | Startup accelerator | Mountain View, United States | 49 | 3% | 9 | Probably Genetic, Multiply Labs, Kopra Bio |
| 2 | SOSV | Venture capital firm | Princeton, United States | 16 | 1% | 6 | Prolific Machines, Farm Minerals, Rybodyn |
| 3 | Khosla Ventures | Venture capital firm | Menlo Park, United States | 14 | 1% | 5 | Probably Genetic, Moonwalk Biosciences, Prellis Biologics |
| 4 | SOSV SF & NY (Fka IndieBio) | Venture capital firm | San Francisco, United States | 13 | 1% | 6 | Prolific Machines, Farm Minerals, Rybodyn |
| 5 | RA Capital Management | Startup incubator | Boston, United States | 13 | 1% | 1 | Element Biosciences |
| 6 | Plug and Play | Startup accelerator | Sunnyvale, United States | 13 | 1% | 4 | ImpriMed, Prellis Biologics, WittGen Biotechnologies |
| 7 | National Science Foundation | Entrepreneurship program | Alexandria, United States | 12 | 1% | 2 | BreezeBio, Culture Biosciences |
| 8 | Alumni Ventures | Angel group | Manchester, United States | 12 | 1% | 1 | ParcelBio |
| 9 | OrbiMed | Private equity firm | New York, United States | 12 | 1% | 5 | Terremoto Biosciences, Angitia Biopharmaceuticals, Mirador Therapeutics |
| 10 | Andreessen Horowitz | Venture capital firm | Menlo Park, United States | 10 | 1% | 1 | BigHat Biosciences |
| 11 | Pioneer Fund | Startup accelerator | Toronto, Canada | 10 | 1% | 3 | Kopra Bio, ParcelBio, Angstrom AI |
| 12 | Bristol-Myers Squibb | Venture capital firm | New York, United States | 9 | 1% | 1 | BigHat Biosciences |
| 13 | Alexandria Venture Investments | Venture capital firm | Pasadena, United States | 9 | 1% | 3 | TwoStep Therapeutics, Lycia Therapeutics, Aspen Neuroscience |
| 14 | ARCH Venture Partners | Venture capital firm | Chicago, United States | 9 | 1% | 2 | Moonwalk Biosciences, Mirador Therapeutics |
| 15 | 500 Global | Startup accelerator | Palo Alto, United States | 8 | 1% |
Table 3. Biotech startups in California, United States: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 1,257 | 80% | $67.7B |
| Software | 331 | 21% | $14.1B |
| Artificial intelligence | 224 | 14% | $9.9B |
| Hardware | 57 | 4% | $3.0B |
| Fintech | 16 | 1% | $959.5M |
| Energy | 15 | 1% | $678.2M |
| Cybersecurity | 14 | 1% | $571.2M |
| Commerce | 6 | 0% | $128.3M |
| Education | 6 | 0% | $3.3M |
Table 4. Biotech startups in California, United States by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
Table 5. Biotech startups in California, United States by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Cities
| Cities | Companies | Share |
|---|---|---|
| San Francisco | 396 | 25% |
| San Diego | 231 | 15% |
| Palo Alto | 87 | 6% |
| South San Francisco | 69 | 4% |
| Berkeley | 57 | 4% |
| Los Angeles | 56 | 4% |
| Menlo Park | 47 | 3% |
| Mountain View | 43 | 3% |
| Redwood City | 39 | 2% |
| Irvine | 33 | 2% |
| San Jose | 28 | 2% |
| San Carlos | 28 | 2% |
Table 6. Biotech startups in California, United States by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 1 | 0% | $6.0M |
| October 2026 | 24 | 11% | $814.0M |
| September 2026 | 22 | 10% | $823.1M |
| August 2026 | 15 | 7% | $477.2M |
| July 2026 | 17 | 7% | $610.4M |
| June 2026 | 20 | 9% | $1.0B |
| May 2026 | 19 | 8% | $381.5M |
| April 2026 | 11 | 5% | $385.1M |
| March 2026 | 24 | 11% | $389.4M |
| February 2026 | 12 | 5% | $414.9M |
| January 2026 | 34 | 15% | $1.5B |
| December 2025 | 22 | 10% | $886.5M |
| November 2025 | 7 | 3% | $397.0M |
Table 7. Biotech startups in California, United States: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 199 | 13% | $6.8B |
| 2025 | 176 | 11% | $6.3B |
| 2024 | 158 | 10% | $5.7B |
| 2023 | 117 | 7% | $2.6B |
| 2022 | 127 | 8% | $3.4B |
| 2021 | 143 | 9% | $7.8B |
Table 8. Biotech startups in California, United States by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 254 | 16% |
| 2020 to 2022 | 259 | 17% |
| 2015 to 2019 | 482 | 31% |
| 2010 to 2014 | 261 | 17% |
| Before 2010 | 303 | 19% |
Table 9. Biotech startups in California, United States by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 652 | 42% |
| 11 to 50 | 639 | 42% |
| 51 to 100 | 139 | 9% |
| 101 to 250 | 62 | 4% |
| 251 to 500 | 15 | 1% |
| 501 to 1,000 | 13 | 1% |
| 1,001 to 5,000 | 5 | 0% |
| 5,001 to 10,000 | 4 | 0% |
| 10,001 or more | 7 | 0% |
Table 10. Biotech startups in California, United States by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its headquarters is in California, United States. On 16 November 2026 that is 1,577 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 30 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 1,577 rows: 332 have no round amount, 0 no city and 216 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in California, United States are on the list?
- 1,577, in the file dated 16 November 2026. 228 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 1,577 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $349.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.